Pharmaceuticals APAC News & Press Release Distribution

ASEAN accepts mutually recognized COVID-19 vaccination certificates

DENPASAR, Indonesia, May 17, 2022 /PRNewswire/ -- ASEAN Member States collectively recognize the COVID-19 vaccination certificate to be applied in Southeast Asia. Health Ministers of ASEAN countries endorsed the decision during the 15th ASEAN Health Ministers Meeting (15th AHMM) inNusa Dua, Bali, ...

2022-05-17 19:14 1924

ASEAN accepts mutually recognized COVID-19 vaccination certificates

ABL AND ODIMMA THERAPEUTICS JOIN FORCES IN PERSONALIZED CANCER IMMUNOTHERAPY

PARIS, May 17, 2022 /PRNewswire/ -- ABL Europe (ABL ), a pure play contract development and manufacturing organization (CDMO) specialized in development and manufacturing of virus for vaccine candidates, gene and cancer therapies and Odimma Therapeutics (Od...

2022-05-17 15:00 1972

CStone announces final PFS analysis of a registrational study of sugemalimab in patients with stage III NSCLC further demonstrates its robust efficacy and significant clinical benefits shown in interim analysis

* Sugemalimab is the world's first anti-PD-(L)1 monoclonal antibody to significantly improve progression-free survival (PFS) in patients with stage III non-small cell lung cancer (NSCLC) without disease progression following concurrent or sequential chemoradiotherapy * The National Medical Pr...

2022-05-17 08:02 2632

Ascletis (1672.HK) Included in MSCI China Small Cap Index

HANGZHOU and SHAOXING, China, May 16, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that it will be included in the MSCI China Small Cap Index, effective after the market close onMay 31, 2022. Morgan Stanley Capital International (MSCI) is a leading provider o...

2022-05-16 20:17 3566

Antengene Announces Commercial Availability of XPOVIO® (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China

-Distribution channels in place to streamline/facilitate patient access. -XPOVIO® will be available in 600 hospitals and 105 DTPs (across China includingBeijing, Shanghai, Guangdong, Jiangsu, Zhejiang, Henan, and Shandong). SHANGHAI and HONG KONG, May 16, 2022 /PRNewswire/ -- Antengene Corporatio...

2022-05-16 11:20 2588

Innovent Will Present Clinical Data of IBI110 (anti-LAG-3 monoclonal antibody) and Other Multiple Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

SAN FRANCISCO and SUZHOU, China, May 16, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and ...

2022-05-16 08:00 3092

Seegene reports first quarter 2022 financial results

* Q1 revenue up 10% QoQ to reach record quarterly high of KRW 451.5 billion * Foundation for sales expansion strengthened through '3 Ct' technology commercialization, Allplex™ RV Master Assay approval, increased PCR instrument sales * "Seegene to secure future growth by targeting syndromic t...

2022-05-13 19:00 2584

Antengene Announces XPOVIO® (selinexor) Data to be Presented at the Upcoming 2022 European Hematology Association Hybrid Congress

SHANGHAI and HONG KONG, May 13, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hema...

2022-05-13 18:00 2529

Antengene Announces Addition of Multiple XPOVIO® Treatment Regimens for Myeloma and Lymphoma in 2022 CSCO Guidelines

SHANGHAI and HONG KONG, May 13, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hema...

2022-05-13 08:30 2314

Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and GalAhead™ Programs at the TIDES USA 2022

GAITHERSBURG, Md. and SUZHOU, China, May 11, 2022 /PRNewswire/ -- Sirnaomics Ltd. ("Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it will present the latest developments o...

2022-05-11 13:05 2123

Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab) for Immune Restoration/Functional Cure of HIV-1 Infected Patients

HANGZHOU, China and SHAOXING, China, May 11, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today the Investigational New Drug (IND) application approval of ASC22 (Envafolimab) by U.S. Food and Drug Administration (FDA) for the indication of immune restoration/functi...

2022-05-11 08:40 2016

RhoVac AB announces Database Lock in its clinical phase IIb trial of onilcamotide

STOCKHOLM, Sweden, May 11, 2022 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company,announced on May 10th, 2022, that its phase IIb study in prostate cancer, BRaVac, has reached "Database Lock". This means that all data from the trial is now finally reported, cleaned and...

2022-05-11 06:42 1711

Bora Pharmaceuticals acquires Eden Biologics CDMO Assets

Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market TAIPEI, May 10, 2022 /PRNewswire/ -- Taiwan-based premier international contract development and manufacturing organization (CDMO) Bora Pharmaceuticals recently announced the esta...

2022-05-10 17:53 2719

Bora Pharmaceuticals acquires Eden Biologics CDMO Assets

OMRON Healthcare Unveils Long-term Corporate Vision, "Going for ZERO, Preventive Care for Health of Society"

- Aiming to Realize 3 Zeros: "Zero Cerebrovascular and Cardiovascular Events," "Zero Aggravation of Respiratory Diseases" and "Zero Restrictions on Daily Activities Due to Chronic Pain" - KYOTO, Japan, May 10, 2022 /PRNewswire/ -- In March 2022, OMRON Group announced a new long-term vision, "Sha...

2022-05-10 13:00 1928

Robert Wessman-led Aztiq completes $500 million transaction in an alliance with Innobic to create an international pharma powerhouse

* The Consortium jointly, through Aztiq II HoldCo, has completed the acquisition of a 100% stake in Alvogen Emerging Markets Holdings Limited, thereby becoming the leading shareholders in Lotus Pharmaceuticals and Adalvo * Róbert Wessman, Chairman and CEO of Alvogen and Founder of Aztiq Pharma ...

2022-05-10 11:00 2332

Robert Wessman-led Aztiq completes $500 million transaction in an alliance with Innobic to create an international pharma powerhouse

Brii Bio Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Omicron BA.2 Subvariant

* Studies conducted by independent labs demonstrate the amubarvimab/romlusevimab combination retains neutralizing activity against COVID-19 Omicron variant * Review of the monoclonal antibody combination therapy is underway by the U.S. Food and Drug Administration (FDA) for Emergency Use Auth...

2022-05-09 19:46 2137

Series A financing round lays foundation for international growth of digital cancer therapeutics Mika

New investors with a successful track record in digital oncology support German Digital Therapeutics (DTx) company Fosanis to broaden patient access of Mika – an app-based DTx platform empowering people affected by cancer. BERLIN, LAUSANNE,Switzerland, BARCELONA,Spain and MUNICH, May 9, 2022 /PR...

2022-05-09 19:35 1886

Takeda Malaysia receives coveted HR accolades by creating an exceptional people experience

Key points: * Takeda Malaysia receives Great Place to Work® award for the first time and Top Employer certification for the sixth consecutive year. * A significant majority of employees surveyed in Malaysia in 2021 Great Place to Work® Trust Index stated that Takeda is a great workplace. * ...

2022-05-09 09:05 2100

Takeda Singapore receives coveted HR accolades by creating an exceptional people experience

Key points: * Takeda Singapore receives Great Place to Work® award for the first time and Top Employer certification for the sixth consecutive year. * A significant majority of employees surveyed in Singapore in 2021 Great Place to Work® Trust Index stated that Takeda is a great workplace. ...

2022-05-09 09:00 1818

ExoCoBio Receives Japanese Patent for Alleviating Dermatitis with Adipose Stem Cell-Derived Exosome

* To lay a technological foundation for developing exosome-based medicines and cosmetic products for dermatitis treatment * To prove the technological feasibility of ExoSCRT™ for the mass-production of the world's best exosomes with high efficacy SEOUL, Korea, May 9, 2022 /PRNewswire/ -- ExoC...

2022-05-09 07:00 3035